BD worked with JCI to create a Gold Standard benchmarked safety program called Preventing Risks of Infections and Medication Errors in IV Therapy (PRIME)
First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis
XELJANZ is the first and only Janus kinase (JAK) inhibitor approved in Europe for the treatment of polyarticular JIA and juvenile PsA and has received regulatory approval in four indications in the European Union, the most of any JAK inhibitor
Researchers from IIT Bombay and QIMR Berghofer Medical Research Institute, Australia have developed this method, based on the Agilent Cary 630 FTIR Spectrometer
It aims to provide trained healthcare manpower, home care solutions, and end-to-end hospital management services enabling quick & on-demand deployment
New treatment options are critical, as approximately half of all people with heart failure die within five years of diagnosis. Heart failure accounts for more than one million hospitalisations a year in the US
Preliminary data from the first 20 participants in Azerbaijan show antibodies to the SARS-CoV-2 virus spike protein (S-protein) elicited in 100% of cases
Fitterfly has launched an online Prediabetes risk test which is an evidence-based, clinically validated tool for assessing an individual's risk of Prediabetes
The transaction improves patient experience, patient outcomes and aims to reduce health care costs
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
Subscribe To Our Newsletter & Stay Updated
